Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have received a consensus recommendation of “Moderate Buy” from the eight analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, three have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year price target among analysts that have updated their coverage on the stock in the last year is $55.50.

TVRD has been the topic of several analyst reports. BTIG Research reissued a “buy” rating and issued a $15.00 target price on shares of Tvardi Therapeutics in a research note on Wednesday, April 1st. Lucid Cap Mkts raised Tvardi Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. Weiss Ratings reissued a “sell (e+)” rating on shares of Tvardi Therapeutics in a research note on Friday, April 10th. Finally, Wall Street Zen lowered Tvardi Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 4th.

Hedge Funds Weigh In On Tvardi Therapeutics

Several hedge funds have recently added to or reduced their stakes in TVRD. Vanguard Group Inc. increased its holdings in shares of Tvardi Therapeutics by 5.2% in the third quarter. Vanguard Group Inc. now owns 419,167 shares of the company’s stock worth $16,335,000 after acquiring an additional 20,757 shares in the last quarter. American Financial Group Inc. bought a new stake in shares of Tvardi Therapeutics in the fourth quarter worth about $962,000. Vestal Point Capital LP bought a new stake in shares of Tvardi Therapeutics in the third quarter worth about $6,508,000. Geode Capital Management LLC increased its holdings in shares of Tvardi Therapeutics by 6.2% in the fourth quarter. Geode Capital Management LLC now owns 157,133 shares of the company’s stock worth $676,000 after acquiring an additional 9,214 shares in the last quarter. Finally, State Street Corp increased its holdings in shares of Tvardi Therapeutics by 83.7% in the fourth quarter. State Street Corp now owns 115,501 shares of the company’s stock worth $497,000 after acquiring an additional 52,637 shares in the last quarter. Institutional investors and hedge funds own 44.66% of the company’s stock.

Tvardi Therapeutics Stock Up 1.0%

Shares of TVRD opened at $4.00 on Friday. Tvardi Therapeutics has a 12-month low of $2.75 and a 12-month high of $43.65. The firm has a market capitalization of $37.52 million, a PE ratio of -1.29 and a beta of 0.30. The stock’s fifty day simple moving average is $3.44 and its 200-day simple moving average is $3.89.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.08). Analysts anticipate that Tvardi Therapeutics will post -2.1 EPS for the current year.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.